ESC Congress 2005: ISSUE II

September 05, 2005

A new diagnostic and treatment strategy provided an 80% reduction in the one-year recurrence rate and a 92% reduction of total burden of syncope in some forms of neurally-mediated syncope.

This strategy consisted of risk stratification based on simple initial evaluation, early application of an implantable electrocardiographic monitor (Implantable Loop Recorder - ILR), assessment of the exact mechanism of syncope by documenting a spontaneous episode and then prescribing mechanism-based specific therapy.

The previous strategy, in the absence of an electrocardiographic documentation of syncope, was principally guided by the results of tilt testing. Controlled trials of tilt-guided therapy, however, have often failed to show a benefit. In particular, the efficacy of pacemaker therapy was questioned after two recent controlled trials failed to prove superiority of cardiac pacing over placebo. This new research demonstrates that improved patient selection methods lead to significantly better therapy outcomes.

The International Study on Syncope of Uncertain Etiology 2 (ISSUE 2) was a multi-centre, prospective, observational study enrolling 442 patients from centres across Europe and in the US with a diagnosis of suspected neurally-mediated syncope (diagnosis made according to the criteria set by the Guidelines on Syncope of the European Society of Cardiology).

The ILR was placed subcutaneously under local anesthesia (Figure). High fidelity electrocardiographic recordings were captured through patient activation of the device or automatic activation using predefined arrhythmia triggers. The ILR carries an up-front cost of approximately €1.500. Previous studies showed that, when symptom-ECG correlation can be achieved in a substantial number of patients, analysis of the cost per symptom-ECG of the implanted device is more cost-effective than conventional diagnostic methods.

Four hundred and forty two patients with ?3 clinically severe syncopal episodes over two years with normal electrocardiograms and without significant electrocardiographic and cardiac abnormalities were included in the study. Patients with orthostatic hypotension and carotid sinus syncope were excluded. After ILR implantation, patients were followed until the first documented syncopal episode (Phase I). The mechanism of this episode was documented by ILR in 103 patients (mean time of 12±8 months) and guided subsequent therapy. Forty seven patients received a pacemaker because of asystole of a median 11.5 s duration, six patients had anti-tachyarrhythmia therapy (catheter ablation #4, implantable defibrillator #1, antiarrhythmic drug #1); the remaining 50 patients did not receive specific therapy. Following therapy, patients entered an observational period to determine syncope recurrence (Phase II). The table below summarizes recurrence results obtained in the two groups of patients.

The actuarial one-year recurrence rate in the subgroup of 47 patients who received pacemaker therapy was 5% (burden 0.05±0.15 episodes per patient/year), significantly lower than that observed in patients without asystole or bradycardia and of that observed in patients with asystole or bradycardia who did not receive a pacemaker.

The strategy was safe. Severe trauma secondary to syncopal relapse occurred in 2% and mild trauma in 4% of the patients. No patient died for syncope-related causes. In conclusion, this is the first study to demonstrate that a new strategy based on early application of ILR and therapy delayed after documentation of syncope allows a safe mechanism-based effective therapy

ISSUE 2 Steering Committee
Michele Brignole, MD (chairman), Italy
Richard Sutton, MD (co-chairman), UK
Carlo Menozzi, MD (co-chairman), Italy
Angel Moya, MD, Spain
Roberto Garcia-Civera, MD, Spain
David Benditt, MD, USA
Panos Vardas, MD, Greece
Wouter Wieling, MD, The Netherlands
Dietrich Andresen, MD, Germany
Roberta Migliorini, BSc, Italy
David Hollinworth, PhD, UK

Endorsement
European Heart Rhythm Association (EHRA) - formerly Working Group of Pacing of the European Society of Cardiology - a branch of the European Society of Cardiology.
-end-
This study was made possible by a grant from Medtronic Inc.

European Society of Cardiology

Related Pacemaker Articles from Brightsurf:

No need to steer clear of electric cars if you have a pacemaker
A study published in Technology and Health Care shows that four leading brands of e-cars do not trigger electromagnetic interference (EMI) with cardiac implantable electronic devices (CIED).

Developing next-generation biologic pacemakers
University of Houston associate professor of pharmacology Bradley McConnell is helping usher in a new age of cardiac pacemakers by using stem cells found in fat, converting them to heart cells, and reprogramming those to act as biologic pacemaker cells.

U of T Mississauga study identifies 'master pacemaker' for biological clocks
What makes a biological clock tick? According to a new study from U of T Mississauga, the surprising answer lies with a gene typically associated with stem and cancer cells.

Powering a pacemaker with a patient's heartbeat
Implantable pacemakers have without doubt altered modern medicine, saving countless lives by regulating heart rhythm.

Wireless 'pacemaker for the brain' could offer new treatment for neurological disorders
A new neurostimulator developed by engineers at the University of California, Berkeley, can listen to and stimulate electric current in the brain at the same time, potentially delivering fine-tuned treatments to patients with diseases like epilepsy and Parkinson's.

Cleveland clinic- led study shows leadless pacemaker patients experience less complications
Patients receiving leadless pacemakers experience overall fewer short-term and mid-term complications than those receiving traditional transvenous pacemakers, a Cleveland Clinic-led research study found.

What is impact of permanent pacemaker implantation after transcatheter aortic valve replacement?
The need for a patient to have a permanent pacemaker implanted while hospitalized after undergoing a transcatheter aortic valve replacement is a complication associated with worse survival and increased risk of more time spent in the hospital then and in the future.

Ohio State study of brain pacemaker shows promise in slowing decline of Alzheimer's
Researchers at The Ohio State University Wexner Medical Center studied how using an implant -- likened to a pacemaker for the brain -- could help Alzheimer's patients to retain cognitive, behavioral and functional abilities longer while also improving quality of life.

Bacteria as pacemaker for the intestine
For the first time, a research team from the Cell and Developmental Biology (Bosch AG) working group at the Zoological Institute at Kiel University (CAU) has been able to prove that the bacterial colonisation of the intestine plays an important role in controlling peristaltic functions.

Mexican doctors safely reuse donated pacemakers after sterilisation
Mexican doctors have safely reused donated pacemakers after sterilisation, shows a study presented at the 30th Mexican Congress of Cardiology.

Read More: Pacemaker News and Pacemaker Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.